Xspray has doubled its personnel and laboratory space in response to demand for its manufacturing service, which is designed to overcome the drawbacks associated with micronisation.
Following calls for increased transparency PhRMA has published its new clinical trial principles, which contain revisions relating to registration, authors and sponsor disclosure.
US clinical trials firm ChemDiv has bought Russian CRO Prudentas, boosting its presence in the country at a time when the treatment naïve populations in Eastern Europe are increasingly catching the eye of the global pharma and biotech industries.
Finding appropriate subjects in the booming trials market is a major stumbling block for drug firms and CROs, according to a new study by US market analysts Cutting Edge Information
Companies seeking research services in India and China will now be able to use a single contact following an alliance between GVK BIO and Excel, which the companies claim is the first to span the two nations.
Pfizer is the latest company to seek greater control of its Indian subsidiary, falling into step with Swiss drug major Novartis which made a similar move late last month.
Just weeks after expanding its relationship with AstraZeneca, Chinese CRO BioDuro has been asked by Swiss drug major Roche to help with its discovery phase R&D programme.
Sanofi-Aventis had a €5bn ($6.6bn) bid for Solvay’s pharma business rejected, according to media reports, but several other companies are believed to be interested in the Belgian firm.
The Chinese unit of US contract drug discovery firm BioDuro says that AstraZeneca has expand its relationship with the firm to include the optimization of discovery research operations focused on drugs for respiratory and inflammatory disease.
The slashing of pharma’s in-house teams did not help contract sales provider PDII in 2008, with the company recording an operating loss of $36.4m (€28.5m), compared with a $14.3m deficit the previous year.
Indian generics firm Piramal Healthcare says it "has no intention to dilute current ownership levels," but has not commented on rumours that it is in talks with French firm Sanofi Aventis.
Sales and marketing service specialist InVentiv Health slid to a loss in the fourth quarter of 2008, despite posting a 16 per cent hike in net revenues to $248m.
UK company Celsis saw softness in demand across its operating divisions in the third quarter ended December 31, and said it was considering “strategic alternatives” for its laboratory services unit.
Pfizer’s $68bn swoop for Wyeth looks set to start an epidemic of merger madness according to comments by Frost & Sullivan (F&S) analyst Shabeer Hussain.
The WHO has delayed its controversial EB 124/14 amendment that would, according to some groups, broaden the organisation’s definition of “counterfeit” from its current focus on patient health to include infringements of intellectual property.
Senator Richard Moore has criticised transparency laws in Massachusetts, US, which he claims allow pharmaceutical companies to hide payments made to physicians conducting clinical trials.
Recipharm hopes that its new tablet and capsule manufacturing facility in Fontaine-Les-Dijon, France, which significantly expands its dry powder production capacity, will help it broaden its European client base.
Portuguese contract manufacturer Hovione has emerged as the buyer for Pfizer’s production plant in Cork, Ireland, which was put on the block last year.
Parexel has made a bold foray into the troublesome arena of stroke drug development via an alliance with Safe Implementation of Treatments in Stroke (SITS) International, an international network of clinical sites geared up to recruit stroke patients.
A UK judge has warned against the European Commission making rash changes following its report into big pharma blocking generics, arguing that it could damage development of new drugs.
Competition commissioner Neelie Kroes said that some drugmakers operating in the EU are deliberately stalling the introduction of generics, costing European patients around €3bn ($3.87bn) a year more to buy medicines.
European facilities owned by Israel’s Teva Pharmaceuticals and French drugmaker Servier are among the firms raided by the EC’s competition unit earlier this week, according to media reports.
A UK development think-tank has warned against a knee-jerk reaction against conducting clinical trials in India, following the revelation a few weeks ago that dozens of children had lost their lives in studies conducted at a contract research facility.
Next year, drug revenues will grow 5 per cent to $820bn according to IMS Health, as the global downturn, patent expiry and flat-lining growth rates in mature markets all make their presence felt.
The pharmaceutical industry must adapt its processes and strategies to cope with a new, tougher operating environment, according to Stefan Borgas, CEO of Lonza.
Data analysis may be the next aspect of the drug industry to be outsourced if the new virtual drug development network created by GSK and UK software firm InforSense is any indication.
US-based contract research organisation Medelis has founded a European division, Medelis Europe, to bring its expertise in oncology clinical trials design and management to customers wanting to launch drugs in Europe.
Ahead of the “open house” at its facility in Monteriggioni, Siena, Italian machining specialist Marchesini spoke with in-PharmaTechnologist.com about the new plant and its role in the firm's offering to the drug industry.
US CRO group Encorium has signed new contracts worth around $6.2m (€4.1m) under which it will conduct trials of a developmental vaccine on behalf of a global biopharmaceutical company.
Drug development services company PharmaNet saw its share price slashed in half on Friday after downsizing its 2008 revenues and earnings forecasts for the second time this year.
Pharmaceutical major Bristol-Myers Squibb has signed another deal with outsourcing specialist Accenture, this time tapping the firm for IT and financial support services via a 10-year contract worth $550m.
The outsourcing of Phase I trials to India may be allowed by 2009-10 after the Central Drugs Standard Control Organisation (CDSCO) said it is considering changing its stance.
Drug delivery specialist BioAlliance Pharma says that its decision to focus on the oncology and infectious disease markets helped it reduce its half-year 2008 losses.
A new study by US contract services giant Parexel International reveals that the number of marketing applications for NMEs in the US grew 33 per cent in 2007.
in-PharmaTechnologist.com's round-up of developments in pharmaceutical manufacturing features news of SAFC’s new highly potent API plant, ISPE’s Facility of the Year Awards and Israel’s proposed entry into PIC/S.
in-PharmaTechnologist.com’s latest round up of developments in the field of pharmaceutical packaging includes 3S’ counterfeit solution and new machines for Xcelience and Medica.
An insurance policy intended to cover against the pitfalls faced by pharmaceutical manufacturers and distributors has been launched by Lloyds’ underwriter Kiln and broker Jardine Lloyd Thompson (JLT).
US protein manufacture and development services provider American Peptide Company (APC) says that its parent company, Ito Life Sciences (ILS), is to be acquired by fellow Japanese firm Otsuka Chemical.
IT infrastructure and business process services firm Cognizant has cut back its full-year financial forecasts on signs that the downturn in the economy is starting to bite at some of its major clients, particularly those in the healthcare sector.
Pharmaceutical companies in the developed world have already
shifted substantial manufacturing and clinical trial work to
emerging economies such as China and India, but a new study suggest
they are increasingly counting on these...
